BACKGROUND: Inadequate response to cisplatin-based chemotherapy is associated with poor prognosis in patients with advanced malignant testicular germ cell tumours (TGCTs), especially of the nonseminomatous type. Novel chemotherapeutic agents have failed so far to significantly improve the outcome of such patients. The majority of these tumours express low levels of p53, and TP53 mutations are rarely observed. Murine double minute 2 (Mdm2) inhibitors enhance apoptosis in tumours harbouring wild-type p53. OBJECTIVE: We sought to investigate the potential therapeutic value of Mdm2 in TGCT-derived cell lines with the histology of nonseminoma. DESIGN, SETTING, AND PARTICIPANTS: The Mdm2 inhibitor nutlin-3 was evaluated alone and in combination with cisplatin in a panel of germ cell tumour (GCT)-derived cell lines (embryonal carcinomas, being the nonseminomatous stem-cell component) with wild-type (NT2 and 2102EP cells) and mutant (NCCIT cells) p53 status. MEASUREMENTS: Biological consequences of Mdm2 inhibition were determined by analysis of the p53 pathway, cell proliferation, and apoptosis. RESULTS AND LIMITATIONS: Nutlin-3 exhibited significant activity (IC50 2.8 μM) in NT2 and 2102EP (wild-type p53) but not in p53-mutant NCCIT cells (<10% inhibition at 10 μM). At concentrations beyond 500 nM, additive effects were seen for the combination of nutlin-3 and cisplatin in NT2 and 2102EP cells but not in NCCIT cells. This correlated with the induction of p53 and its target p21, suggesting an on-target effect of nutlin-3. Moreover, nutlin-3 (5 μM) and cisplatin (0.5 μM) additively induced caspase cleavage and apoptosis in NT2 cells and 2102-EP cells but not in p53-mutant NCCIT cells. CONCLUSIONS: These results provide strong evidence for further development of pharmacologic Mdm2 inhibition for the treatment of patients suffering from high-risk nonseminomatous TGCT with wild-type p53 status.
BACKGROUND: Inadequate response to cisplatin-based chemotherapy is associated with poor prognosis in patients with advanced malignant testicular germ cell tumours (TGCTs), especially of the nonseminomatous type. Novel chemotherapeutic agents have failed so far to significantly improve the outcome of such patients. The majority of these tumours express low levels of p53, and TP53 mutations are rarely observed. Murine double minute 2 (Mdm2) inhibitors enhance apoptosis in tumours harbouring wild-type p53. OBJECTIVE: We sought to investigate the potential therapeutic value of Mdm2 in TGCT-derived cell lines with the histology of nonseminoma. DESIGN, SETTING, AND PARTICIPANTS: The Mdm2 inhibitor nutlin-3 was evaluated alone and in combination with cisplatin in a panel of germ cell tumour (GCT)-derived cell lines (embryonal carcinomas, being the nonseminomatous stem-cell component) with wild-type (NT2 and 2102EP cells) and mutant (NCCIT cells) p53 status. MEASUREMENTS: Biological consequences of Mdm2 inhibition were determined by analysis of the p53 pathway, cell proliferation, and apoptosis. RESULTS AND LIMITATIONS: Nutlin-3 exhibited significant activity (IC50 2.8 μM) in NT2 and 2102EP (wild-type p53) but not in p53-mutant NCCIT cells (<10% inhibition at 10 μM). At concentrations beyond 500 nM, additive effects were seen for the combination of nutlin-3 and cisplatin in NT2 and 2102EP cells but not in NCCIT cells. This correlated with the induction of p53 and its target p21, suggesting an on-target effect of nutlin-3. Moreover, nutlin-3 (5 μM) and cisplatin (0.5 μM) additively induced caspase cleavage and apoptosis in NT2 cells and 2102-EP cells but not in p53-mutant NCCIT cells. CONCLUSIONS: These results provide strong evidence for further development of pharmacologic Mdm2 inhibition for the treatment of patients suffering from high-risk nonseminomatous TGCT with wild-type p53 status.
Authors: Alessandra di Pietro; Roelof Koster; Wytske Boersma-van Eck; Wendy A Dam; Nanno H Mulder; Jourik A Gietema; Elisabeth G E de Vries; Steven de Jong Journal: Cell Cycle Date: 2012-11-19 Impact factor: 4.534
Authors: Aditya Bagrodia; Byron H Lee; William Lee; Eugene K Cha; John P Sfakianos; Gopa Iyer; Eugene J Pietzak; Sizhi Paul Gao; Emily C Zabor; Irina Ostrovnaya; Samuel D Kaffenberger; Aijazuddin Syed; Maria E Arcila; Raju S Chaganti; Ritika Kundra; Jana Eng; Joseph Hreiki; Vladimir Vacic; Kanika Arora; Dayna M Oschwald; Michael F Berger; Dean F Bajorin; Manjit S Bains; Nikolaus Schultz; Victor E Reuter; Joel Sheinfeld; George J Bosl; Hikmat A Al-Ahmadie; David B Solit; Darren R Feldman Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Anna Phillips; Amina Teunisse; Suzanne Lam; Kirsten Lodder; Matthew Darley; Muhammad Emaduddin; Anja Wolf; Julia Richter; Job de Lange; Matty Verlaan-de Vries; Kristiaan Lenos; Anja Böhnke; Frank Bartel; Jeremy P Blaydes; Aart G Jochemsen Journal: J Biol Chem Date: 2010-07-20 Impact factor: 5.157
Authors: Asfar S Azmi; Amro Aboukameel; Sanjeev Banerjee; Zhiwei Wang; Momin Mohammad; Jack Wu; Shaomeng Wang; Dajun Yang; Philip A Philip; Fazlul H Sarkar; Ramzi M Mohammad Journal: Eur J Cancer Date: 2010-02-13 Impact factor: 9.162
Authors: Matthias Gutekunst; Moshe Oren; Andrea Weilbacher; Michael A Dengler; Christiane Markwardt; Jürgen Thomale; Walter E Aulitzky; Heiko van der Kuip Journal: PLoS One Date: 2011-04-21 Impact factor: 3.240